Aura Biosciences Inc (AURA)
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors. The company’s proprietary platform uses virus-like particles that are either conjugated with drugs or loaded with nucleic acids, with the goal of targeting a range of solid tumor indications. Its lead candidate, bel-sar, is being studied in late-stage development for primary choroidal melanoma and other ocular oncology uses, and in earlier-stage development for bladder cancer. Aura Biosciences was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AURA
|
$5.73
|
-17.9% Downside
|
Fair
|
$18.80
|
169.3% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-6.9x
|
7.2x
|
—
|
752.2 M
|
673.3 M
|
2.2%
|
90.2%
|
7.6
|
—
|
81.5%
|
